期刊
BLOOD
卷 113, 期 11, 页码 2508-2516出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-05-158618
关键词
-
类别
资金
- National Institute of Allergy and Infectious Diseases (NIAID
- Bethesda, MD) [T32- 07 405-16]
- Leukemia & Lymphoma Society (White Plains, NY)
- Cancer Research Institute (New York, NY)
- American Cancer Society (Atlanta, GA)
- NIAID grant [R01 AI055701]
- National Cancer Institute (Bethesda, MD) [CA-117802]
- NJMRC
- Leukemia & Lymphoma Society
We have generated mouse models of non-Hodgkin lymphoma (NHL) that rely on the cooperation between MYC overexpression and B-cell antigen receptor (BCR) signaling for the initiation and maintenance of B-cell lymphomas. Using these mouse models of NHL, we have focused on the identification of BCR-derived signal effectors that are important for the maintenance of NHL tumors. In the present study, we concentrate on Spleen tyrosine kinase (Syk), a nonreceptor tyrosine kinase required to transduce BCR-dependent signals. Using a genetic approach, we showed that Syk expression is required for the survival of murine NHL-like tumors in vitro and that tumor cells deficient in Syk fail to expand in vivo. In addition, a pharmacologic inhibitor of Syk was able to induce apoptosis of transformed B cells in vitro and led to tumor regression in vivo. Finally, we show that genetic or pharmacologic inhibition of Syk activity in human NHL cell lines are generally consistent with results found in the mouse models, suggesting that targeting Syk may be a viable therapeutic strategy. (Blood. 2009;113:2508-2516)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据